PDE-5 Inhibitors for Treatment of Raynaud Phenomenon

Added to existing therapy, these oral agents could boost efficacy.

Raynaud phenomenon (RP) may be primary (idiopathic) or secondary, usually in conjunction with a collagen vascular disorder. The initial treatment of RP consists of measures aimed at avoidance of triggers, including wearing of gloves to avoid cold. Topical nitroglycerin might help some patients, but the initial pharmacologic intervention is usually a calcium channel blocker (CCB). Oral angiotensin-converting enzyme inhibitors (ACE-Is) might also be effective. Recently, interest in the use of phosphodiesterase (PDE)-5 inhibitors has arisen due to their effect on nitric oxide, believed to be involved in RP pathogenesis.

The authors conducted a systematic review of randomized, controlled trials involving sildenafil, tadalafil, or vardenafil for …

Reviewing Author

Jeffrey P. Callen, MD

Disclosures

Consultant / Advisory board XOMA; Eli Lilly; Celgene

Equity Various trust accounts

Editorial boards JAMA Dermatology; UpToDate

Leadership positions in professional societies Association of Professors of Dermatology (President-Elect)